6bf9821d-da67-470f-9650-69d05b056166
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.600
- ANGIOGENESIS+0.600
- IL6_JAK_STAT3_SIGNALING+0.600
- INTERFERON_GAMMA_RESPONSE+0.600
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.500
- INFLAMMATORY_RESPONSE+0.500
- INTERFERON_ALPHA_RESPONSE+0.500
- COMPLEMENT+0.400
- IL2_STAT5_SIGNALING+0.400
- KRAS_SIGNALING_UP+0.400
Top 10 suppressed
- E2F_TARGETS-0.500
- MYC_TARGETS_V2-0.500
- OXIDATIVE_PHOSPHORYLATION-0.500
- G2M_CHECKPOINT-0.400
- MYC_TARGETS_V1-0.400
- DNA_REPAIR-0.300
- HEDGEHOG_SIGNALING-0.300
- CHOLESTEROL_HOMEOSTASIS-0.200
- FATTY_ACID_METABOLISM-0.200
- MITOTIC_SPINDLE-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR22247245 | — | cohortMD2 | 0.925 |
| 2 | SRR5088910 | — | — | 0.906 |
| 3 | cf9ea065-c101-48e2-a1ea-54eb01658eef | — | — | 0.900 |
| 4 | BS_RGPSEMHC | Posterior Fossa Ependymoma | — | 0.899 |
| 5 | TCGA-55-8299-01A-11R-2287-07 | — | cohortMD2 | 0.898 |
| 6 | SRR5088860 | — | — | 0.895 |
| 7 | TCGA-22-4596-01A-01R-1201-07 | — | cohortA1 | 0.894 |
| 8 | TCGA-69-7978-01A-11R-2187-07 | — | cohortA1 | 0.894 |
| 9 | TCGA-63-A5MN-01A-22R-A27Q-07 | — | cohortA1 | 0.892 |
| 10 | SRR10842349 | — | — | 0.890 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.600 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.600 | Remibrutinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.600 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.600 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.500 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.500 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.500 | Inavolisib | — uncovered |
| COMPLEMENT | 0.400 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.400 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.400 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.400 | Inavolisib | — uncovered |
| COAGULATION | 0.300 | Binimetinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.300 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.300 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.200 | Inavolisib | — uncovered |
| APOPTOSIS | 0.200 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.200 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.200 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.200 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.100 | Inavolisib | — uncovered |